Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.63 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023212 | 1.00 | ALDH1A1 (0.71) | ALDH1A1EGLN1SLC2A1LMNAALOX12 | |
| SCHEMBL27872555 | 0.89 | ALDH1A1 (0.77) | ALDH1A1EGLN1LMNA | |
| SCHEMBL6492314 | 0.86 | EGLN1 (0.59) | ALDH1A1EGLN1LMNAALOX12 | |
| SCHEMBL28465492 | 0.84 | ALDH1A1 (0.54) | ALDH1A1EGLN1LMNAALOX12KDR | |
| SCHEMBL1759043 | 0.83 | ALDH1A1 (1.00) | ALDH1A1EGLN1LMNAALOX12 | |
| SCHEMBL29761118 | 0.82 | PARP1 (0.62) | ALDH1A1LMNAALOX12KDR | |
| SCHEMBL11807194 | 0.82 | PARP1 (0.62) | ALDH1A1LMNAALOX12KDR | |
| SCHEMBL9139640 | 0.82 | ALDH1A1 (0.97) | ALDH1A1EGLN1LMNAALOX12 | |
| SCHEMBL7687801 | 0.81 | ALDH1A1 (0.66) | ALDH1A1EGLN1LMNAALOX12 | |
| Hydrochloric Acid SCHEMBL7692786 | 0.80 | ALDH1A1 (0.64) | ALDH1A1EGLN1LMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | ZHUANG LINGHANG (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1333831-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002036734-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | POLI, CYP51A1, DUT | ALDH1A1 1974/4885EGLN1 2187/4885SLC2A1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.